Gain Therapeutics Stock Net Asset
| GANX Stock | USD 1.75 0.11 5.91% |
Gain Therapeutics fundamentals help investors to digest information that contributes to Gain Therapeutics' financial success or failures. It also enables traders to predict the movement of Gain Stock. The fundamental analysis module provides a way to measure Gain Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gain Therapeutics stock.
Gain | Net Asset |
Gain Therapeutics Company Net Asset Analysis
Gain Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Gain Therapeutics Net Asset | 18.61 M |
Most of Gain Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gain Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Net Asset. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Gain Net Tangible Assets
Net Tangible Assets |
|
Based on the recorded statements, Gain Therapeutics has a Net Asset of 18.61 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Gain Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.Gain Therapeutics is currently under evaluation in net asset category among its peers.
Gain Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Gain Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gain Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gain Therapeutics' value.| Shares | Ubs Group Ag | 2024-09-30 | 8.5 K | Jones Financial Companies Lllp | 2024-06-30 | 7 K | Tower Research Capital Llc | 2024-09-30 | 4.8 K | Simplex Trading, Llc | 2024-09-30 | 4.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 4.8 K | Creekmur Asset Management Llc | 2024-09-30 | 4.4 K | Bank Of America Corp | 2024-06-30 | 3.5 K | Wells Fargo & Co | 2024-09-30 | 2.6 K | Group One Trading, Lp | 2024-09-30 | 1.4 K | Gotham Asset Management, Llc | 2024-09-30 | 334.6 K | Hohimer Wealth Management, Llc | 2024-06-30 | 330 K |
Gain Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 38.06 M | ||||
| Shares Outstanding | 26.53 M | ||||
| Shares Owned By Insiders | 5.09 % | ||||
| Shares Owned By Institutions | 7.96 % | ||||
| Number Of Shares Shorted | 718.74 K | ||||
| Price To Book | 5.54 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (7.66 M) | ||||
| EBITDA | (22.17 M) | ||||
| Net Income | (22.27 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Short Ratio | 1.65 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 7.4 | ||||
| Number Of Employees | 29 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 49.34 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (60.78 M) | ||||
| Working Capital | 12.83 M | ||||
| Net Asset | 18.61 M |
About Gain Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.